共 214 条
[1]
Etxabe J(1993)Acromegaly: an epidemiological study J Endocrinol Invest 16 181-187
[2]
Gaztambide S(2004)Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA) Eur J Endocrinol 151 439-446
[3]
Latorre P(2009)Guidelines for acromegaly management: an Update J Clin Endocrinol Metab 94 1509-1517
[4]
Vazquez JA(2000)Davis RJ.T reatment of acromegaly with the growth hormone-receptor antagonist pegvisomant N Engl J Med 342 1171-1177
[5]
Mestron A(1994)Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly Eur J Endocrinol 130 229-234
[6]
Webb SM(1999)Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion Clin Endocrinol 50 245-251
[7]
Astorga R(2004)One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel Clin Endocrinol 60 734-740
[8]
Benito P(2006)Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial Clin Endocrinol (Oxf) 65 320-326
[9]
Catala M(2011)Efficacy and acceptability of lanreotide Autogel Exp Clin Endocrinol Diabetes 119 156-162
[10]
Gaztambide S(2003) 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR Clin Endocrinol (Oxf) 58 288-295